UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Overview of Determination of Biopharmaceutical Properties for Development Candidate Selection

Current protocols, 2023-11, Vol.3 (11), p.e926-n/a

Yazdanian, Mehran

2023

Volltextzugriff (PDF)

Discovery and Characterization of 6-{4-[3-(R)-2-Methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, Irdabisant): A Potent, Selective Histamine H3 Receptor Inverse Agonist

Journal of medicinal chemistry, 2011-07, Vol.54 (13), p.4781-4792

2011

Volltextzugriff (PDF)

New directions in pharmaceutical amorphous materials and amorphous solid dispersions, a tribute to Professor George Zografi – Proceedings of the June 2016 Land O’Lakes Conference

AAPS open, 2017-08, Vol.3 (1), p.1-14, Article 7

2017

Volltextzugriff (PDF)

Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery

International journal of pharmaceutics, 2000-11, Vol.208 (1), p.1-11

2000

Volltextzugriff (PDF)

Microparticulate uptake mechanisms of in-vitro cell culture models of the respiratory epithelium

Journal of pharmacy and pharmacology, 2001-01, Vol.53 (1), p.57-66

2001

Volltextzugriff (PDF)

P-glycoprotein efflux pump expression and activity in Calu-3 cells

Journal of pharmaceutical sciences, 2001-05, Vol.90 (5), p.647-658

2001

Volltextzugriff (PDF)

Modulation of P-glycoprotein activity in Calu-3 cells using steroids and β-ligands

International journal of pharmaceutics, 2001-10, Vol.228 (1), p.171-179

2001

Volltextzugriff (PDF)

Multidrug resistance-associated protein-1 functional activity in Calu-3 cells

The Journal of pharmacology and experimental therapeutics, 2001-09, Vol.298 (3), p.1199

2001

Volltextzugriff (PDF)

Evolution of Choice of Solubility and Dissolution Media After Two Decades of Biopharmaceutical Classification System

The AAPS journal, 2017-07, Vol.19 (4), p.989-1001

2017

Volltextzugriff (PDF)

Commentary: Why Pharmaceutical Scientists in Early Drug Discovery Are Critical for Influencing the Design and Selection of Optimal Drug Candidates

AAPS PharmSciTech, 2018, Vol.19 (1), p.1-10

2018

Volltextzugriff (PDF)

Overview of Determination of Biopharmaceutical Properties for Development Candidate Selection

Current Protocols in Pharmacology, 2013-03, Vol.60 (1), p.9.17.1-9.17.8

Yazdanian, Mehran

2013

Volltextzugriff (PDF)

Lipophilicity in Drug Development: Too Much or Not Enough?

The AAPS journal, 2016-09, Vol.18 (5), p.1095-1100

2016

Volltextzugriff (PDF)

Ionic interactions of fatty acid monolayers at the air/water interface

Langmuir, 1990-06, Vol.6 (6), p.1093-1098

1990

Volltextzugriff (PDF)

The effect of freezing on cattle skin permeability

International journal of pharmaceutics, 1994-02, Vol.103 (1), p.93-96

Yazdanian, Mehran

1994

Volltextzugriff (PDF)

A structure–Permeability study of small drug-like molecules

Bioorganic & medicinal chemistry letters, 2003-02, Vol.13 (4), p.719-722

2003

Volltextzugriff (PDF)

CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity

Molecular cancer therapeutics, 2012-04, Vol.11 (4), p.930-941

2012

Volltextzugriff (PDF)

In Vitro Blood–Brain Barrier Permeability of Nevirapine Compared to Other HIV Antiretroviral Agents

Journal of pharmaceutical sciences, 1998-03, Vol.87 (3), p.306-310

1998

Volltextzugriff (PDF)

2,7-Disubstituted-Pyrrolotriazine Kinase Inhibitors with an Unusually High Degree of Reactive Metabolite Formation

Chemical research in toxicology, 2011-11, Vol.24 (11), p.1994-2003

2011

Volltextzugriff (PDF)

Evaluation of an accelerated Caco-2 cell permeability model

Journal of pharmaceutical sciences, 2000-03, Vol.89 (3), p.336

2000

Volltextzugriff (PDF)

Discovery and Characterization of 6-{4-[3-( R )-2-Methylpyrrolidin-1-yl)propoxy]phenyl}-2 H -pyridazin-3-one (CEP-26401, Irdabisant): A Potent, Selective Histamine H 3 Receptor Inverse Agonist

Journal of medicinal chemistry, 2011-07, Vol.54 (13), p.4781-4792

2011

Volltextzugriff (PDF)

CEP-32496: A Novel Orally Active BRAFV600E Inhibitor with Selective Cellular and In Vivo Antitumor Activity

Molecular cancer therapeutics, 2012-04, Vol.11 (4), p.930-941

2012

Volltextzugriff (PDF)

George Zografi: researcher and educator

Pharmaceutical research, 2006-10, Vol.23 (10), p.2235-2238

2006

Volltextzugriff (PDF)

Blood–brain barrier properties of human immunodeficiency virus antiretrovirals

Journal of pharmaceutical sciences, 1999-10, Vol.88 (10), p.950-954

Yazdanian, Mehran

1999

Volltextzugriff (PDF)

Early development GMPs for small-molecule specifications: an industry perspective (part v)

Pharmaceutical technology Europe, 2012-11, Vol.24 (11), p.26

2012

Volltextzugriff (PDF)

P-glycoprotein efflux pump expression and activity in Calu-3 cells

Journal of pharmaceutical sciences, 2001-05, Vol.90 (5), p.645

2001

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Aktive Filter

ThemaCaco-2 Cells

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(31)

Publikationsform

Sprache

Englisch
(35)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Overview of Determination of Biopharmaceutical Properties for Development Candidate Selection

Discovery and Characterization of 6-{4-[3-(R)-2-Methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, Irdabisant): A Potent, Selective Histamine H3 Receptor Inverse Agonist

New directions in pharmaceutical amorphous materials and amorphous solid dispersions, a tribute to Professor George Zografi – Proceedings of the June 2016 Land O’Lakes Conference

Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery

Microparticulate uptake mechanisms of in-vitro cell culture models of the respiratory epithelium

P-glycoprotein efflux pump expression and activity in Calu-3 cells

Modulation of P-glycoprotein activity in Calu-3 cells using steroids and β-ligands

Multidrug resistance-associated protein-1 functional activity in Calu-3 cells

Evolution of Choice of Solubility and Dissolution Media After Two Decades of Biopharmaceutical Classification System

Commentary: Why Pharmaceutical Scientists in Early Drug Discovery Are Critical for Influencing the Design and Selection of Optimal Drug Candidates

Overview of Determination of Biopharmaceutical Properties for Development Candidate Selection

Lipophilicity in Drug Development: Too Much or Not Enough?

Ionic interactions of fatty acid monolayers at the air/water interface

The effect of freezing on cattle skin permeability

A structure–Permeability study of small drug-like molecules

CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity

In Vitro Blood–Brain Barrier Permeability of Nevirapine Compared to Other HIV Antiretroviral Agents

2,7-Disubstituted-Pyrrolotriazine Kinase Inhibitors with an Unusually High Degree of Reactive Metabolite Formation

Evaluation of an accelerated Caco-2 cell permeability model

Discovery and Characterization of 6-{4-[3-( R )-2-Methylpyrrolidin-1-yl)propoxy]phenyl}-2 H -pyridazin-3-one (CEP-26401, Irdabisant): A Potent, Selective Histamine H 3 Receptor Inverse Agonist

CEP-32496: A Novel Orally Active BRAFV600E Inhibitor with Selective Cellular and In Vivo Antitumor Activity

George Zografi: researcher and educator

Blood–brain barrier properties of human immunodeficiency virus antiretrovirals

Early development GMPs for small-molecule specifications: an industry perspective (part v)

P-glycoprotein efflux pump expression and activity in Calu-3 cells

Aktive Filter

Suchergebnisse filtern